Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: A multicenter survey

R. Zeiser, A. Burchert, C. Lengerke, M. Verbeek, K. Maas-Bauer, S. K. Metzelder, S. Spoerl, M. Ditschkowski, M. Ecsedi, K. Sockel, F. Ayuk, S. Ajib, F. S. De Fontbrune, I. K. Na, L. Penter, U. Holtick, D. Wolf, E. Schuler, E. Meyer, P. ApostolovaH. Bertz, R. Marks, M. Lübbert, R. Wäsch, C. Scheid, F. Stölzel, R. Ordemann, G. Bug, G. Kobbe, R. Negrin, M. Brune, A. Spyridonidis, A. Schmitt-Gräff, W. Van Der Velden, G. Huls, S. Mielke, G. U. Grigoleit, J. Kuball, R. Flynn, G. Ihorst, J. Du, B. R. Blazar, R. Arnold, N. Kröger, J. Passweg, J. Halter, G. Socié, D. Beelen, C. Peschel, A. Neubauer, J. Finke, J. Duyster, N. Von Bubnoff

Research output: Contribution to journalArticlepeer-review

360 Scopus citations


Despite major improvements in allogeneic hematopoietic cell transplantation over the past decades, corticosteroid-refractory (SR) acute (a) and chronic (c) graft-versus-host disease (GVHD) cause high mortality. Preclinical evidence indicates the potent anti-inflammatory properties of the JAK1/2 inhibitor ruxolitinib. In this retrospective survey, 19 stem cell transplant centers in Europe and the United States reported outcome data from 95 patients who had received ruxolitinib as salvage therapy for SR-GVHD. Patients were classified as having SR-aGVHD (n=54, all grades III or IV) or SR-cGVHD (n=41, all moderate or severe). The median number of previous GVHD-therapies was 3 for both SR-aGVHD (1-7) and SR-cGVHD (1-10). The overall response rate was 81.5% (44/54) in SR-aGVHD including 25 complete responses (46.3%), while for SR-cGVHD the ORR was 85.4% (35/41). Of those patients responding to ruxolitinib, the rate of GVHD-relapse was 6.8% (3/44) and 5.7% (2/35) for SR-aGVHD and SR-cGVHD, respectively. The 6-month-survival was 79% (67.3-90.7%, 95% confidence interval (CI)) and 97.4% (92.3-100%, 95% CI) for SR-aGVHD and SR-cGVHD, respectively. Cytopenia and cytomegalovirus-reactivation were observed during ruxolitinib treatment in both SR-aGVHD (30/54, 55.6% and 18/54, 33.3%) and SR-cGVHD (7/41, 17.1% and 6/41, 14.6%) patients. Ruxolitinib may constitute a promising new treatment option for SR-aGVHD and SR-cGVHD that should be validated in a prospective trial.

Original languageEnglish (US)
Pages (from-to)2062-2068
Number of pages7
Issue number10
StatePublished - Oct 1 2015

Bibliographical note

Funding Information:
FA, UH, CS, GB, JK, NK, NVB: Research support from Novartis, Bristol Meyer Squibb. DW: grants and personal fees from Novartis. RZ: Speakers fee from Bristol Meyer Squibb, travel grant from Gilead. All grants from Novartis were outside/unrelated to the submitted work. The other authors declare no conflict of interest.

Publisher Copyright:
© 2015 Macmillan Publishers Limited.


Dive into the research topics of 'Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: A multicenter survey'. Together they form a unique fingerprint.

Cite this